Viking's Obesity Drug Clears a Key Hurdle — But Can a $4 Billion Biotech Outrun Lilly and Novo to Market?

Shares surged 12.5% to $33.69 after Viking Therapeutics disclosed that its lead weight-loss drug advanced into Phase 3 trials, a milestone that validates the science but sets the clock ticking on a brutal cash-burn race against two entrenched giants already selling obesity pills.

• A 14.7% Weight-Loss Result in 13 Weeks Got the FDA's Attention

The Phase 2 VENTURE study produced up to 14.7% mean body weight reduction after just 13 weekly injections "with no sign of plateau." That is a strong mid-stage showing — up to 97% of treated participants lost at least 5% of their weight, and up to 80% lost at least 10%, versus negligible results on placebo. The data persuaded the FDA to green-light Phase 3, but investors should note: mid-stage results routinely shrink when tested in larger, more diverse populations.

• Two Late-Stage Trials Are Enrolled, but Results Won't Come Until Late 2027

VANQUISH-1 enrolled roughly 4,500 patients by November 2025, and VANQUISH-2 wrapped enrollment at approximately 1,000 patients in Q1 2026.

Both are 78-week, randomized, placebo-controlled studies proceeding on schedule, with readouts expected in the second half of 2027. That leaves at least a year of pure waiting — and spending — before investors learn whether the drug actually works at scale.

• Cash Is Draining Fast for a Company With Zero Revenue

Viking burned $239 million in operating cash in the first half of 2026 alone, while R&D spending hit $265.9 million — up from $101.5 million a year earlier.

Management says the remaining $502 million cash balance should fund operations into 2028, but the planned oral Phase 3 launch in Q4 2026 will add a new cost layer. A dilutive stock offering before Phase 3 data drops is a real possibility.

• Eli Lilly and Novo Nordisk Already Own This Market

Lilly and Novo hold a roughly 60%-40% split of the obesity drug market, and Lilly's oral pill already reached the U.S. market in April 2026. Viking's pitch — that it could become the first oral dual GLP-1/GIP agonist to reach market — offers a scientific distinction, but commercializing against two companies with established sales forces and billion-dollar marketing budgets is an entirely different challenge. With the obesity drug market projected to reach $100 billion by 2030, even a small slice justifies today's ~$4 billion market cap — if the drug clears Phase 3.